Greenwich LifeSciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on the stock and has a $50.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Yi Chen’s rating is based on several factors, primarily the company’s strengthened liquidity and the anticipated impact on clinical execution. Greenwich LifeSciences extended its runway into 2026 by combining year-end cash reserves with fresh ATM proceeds, and management still has supplementary financing avenues ready should the trial pipeline demand additional resources.
Yi Chen also placed weight on the operational and clinical de-risking now that commercially manufactured GP2 vials have FDA clearance for FLAMINGO-01 and are poised for immediate deployment across the U.S. sites. Early readouts from the non-HLA-A*02 cohort showed an approximately 80% recurrence reduction, matching previous HLA-specific results and effectively expanding the addressable population; this underscores both the durability of the signal and the rationale behind reiterating the Buy rating and $50 target price.